Humedix and Huons Meditech Sign Tripartite MOU with V&Co to Expand AI-powered Skin Diagnostics Business

▲ On May 6, Humedix and Huons Meditech signed an MOU with V&Co to promote collaboration in aesthetics business.

Huons Group affiliates Humedix and Huons Meditech have entered into a strategic partnership with V&Co to create new business opportunities in AI-powered skin diagnostics and aesthetic medicine.

Humedix (CEO Kang Min-jong) and Huons Meditech (CEO Ha Chang-woo) announced on May 6 that they signed a tripartite memorandum of understanding (MOU) with V&Co (CEO Choi Won-seok) to strengthen collaboration in the aesthetics sector.

The agreement aims to combine each company’s technological capabilities and business expertise to create synergies in the field of aesthetic dermatology diagnostics and establish new data-driven business models. Building on this partnership, the three companies plan to develop concrete business models in phases and execution strategies while pursuing practical outcomes.

V&Co’s flagship solution, SKENA, is an AI-based skin diagnostic device designed to analyze and assess skin conditions with precision. By integrating ultrasound technology with contact measurement, the system quantitatively evaluates collagen density and dermal layer balance, providing advanced data to support personalized skin consultations and treatment planning.

Humedix and Huons Meditech expect that SKENA will enhance treatment consultation at partner medical institutions by enabling more effective patient counseling based on skin diagnostic data from SKENA.

The companies also plan to strengthen joint marketing efforts through webinars, academic programs, and expanded engagement with medical professionals. Leveraging Humedix’s strong market presence and network along with Huons Meditech’s global business capabilities, they aim to accelerate SKENA’s market expansion both domestically and internationally.

Going forward, the three companies will also pursue technical collaboration in areas such as personalized treatment recommendation algorithms and enhancing product competitiveness by utilizing the skin diagnostic data accumulated through SKENA.

“This partnership is meaningful in that it creates new business opportunities by connecting skin diagnosis with aesthetic solutions,” said Kang Min-jong, CEO of Humedix. “We will continue to expand collaboration across joint marketing, clinical applications, educational programs, overseas market entry, and the development of connected products based on each company’s unique strengths.”

Ha Chang-woo, CEO of Huons Meditech, added, “Through our strategic collaboration with V&Co, we aim to introduce SKENA to global markets and lead innovation at the forefront of the aesthetics industry.”

Choi Won-seok, CEO of V&Co, said, “The paradigm of skin diagnosis is shifting from experience-based judgment to data-driven precision. Through our collaboration with Huons Group, we believe that SKENA will play a central role in paradigm shift and help redefine standards in the aesthetics industry.”